Enanta Keeps the Lights On with MAVYRET Royalties as Pipeline Murmurs to 2026-29

Executive snapshot: ENTA, EPS, and the royalty treadmill

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) delivered its fiscal second‑quarter update for the period ended March 31, 2026. The headline is stubbornly straightforward: a top line supported by MAVYRET/MAVIRET royalties from AbbVie, with a cash runway stretching into fiscal 2029. There’s a quiet note for those who chase EPS and consensus expectations — the release does not provide an EPS figure or an EPS consensus, nor does it issue a formal revenue forecast. In other words, the quarter’s undercard contains the smiles of royalties and the cliffhanger of pipeline milestones.

Key numbers at a glance

Ticker / market: ENT A; NASDAQ: ENTA
Q2 2026 total revenue: $17.2 million (vs. $14.9 million in the year-ago quarter)
Primary revenue driver: Ongoing royalties from AbbVie’s MAVYRET/MAVIRET
Ongoing royalty arrangement: 54.5% of Enanta’s ongoing royalty revenue from MAVYRET is paid to OMERS (royalty sale transaction, affecting post-2023 royalties)
Cash position: $227 million in cash and marketable securities (as of March 31, 2026)
Runway: Fund operations into fiscal 2029
Near-term milestones: EDP-978 Phase 1 dosing initiated; topline data anticipated in 4Q 2026
Pipeline catalysts: IND for EPS-3903; nomination of an MRGPRX2 development candidate in 2H 2026; Zelicapavir activities for RSV

What Enanta delivered and what it means

The quarterly revenue growth was driven by AbbVie’s MAVYRET/MAVIRET royalties, underscoring the company’s dependence on partner sales cadence rather than internal commercialization. The company highlights a robust balance sheet—the $227 million cash and marketable securities buffer—providing operating flexibility as it advances multiple early- to mid-stage programs.

Management emphasized discipline around its immunology portfolio, with progress on multiple fronts: EDP-978, a KIT inhibitor for chronic urticaria, is advancing in a Phase 1 trial with topline data expected in the fourth quarter of 2026; EPS-3903 (an oral STAT6 inhibitor) is on track for an IND filing, and the company plans to nominate an MRGPRX2 development candidate in the second half of 2026. Zelicapavir remains a focus for enabling activities in RSV, aligning with Enanta’s strategy to keep a pipeline cadence even as royalties fill the near-term ledger.

Near-term catalysts and what to watch

EDP-978 Phase 1: Dosing initiated; topline data expected in 4Q 2026. Any favorable safety or pharmacokinetic readouts could sustain enthusiasm for Enanta’s platform.
EPS-3903 IND: A potential inflection point if the STAT6 inhibitor demonstrates a clean path to clinic and signals collaboration or licensing upside.
MRGPRX2 development candidate: Nominations in 2H 2026 could broaden Enanta’s mechanistic reach in immunology and allergy markets.
Zelicapavir for RSV: Ongoing enabling activities may set the stage for a pivotal study roadmap, subject to regulatory pacing and RSV market dynamics.

Balance sheet and runway: a quiet insurance policy

The company’s liquidity cushion—carrying $227 million in cash and marketable securities as of March 31, 2026—provides ample runway for late-stage data reads and potential milestone-driven value realization. The arrangement that channels a portion of MAVYRET royalties to OMERS adds a governance nuance to the revenue story: Enanta retains the majority of the royalty stream, but a meaningful slice is redirected to a pension-equity vehicle, which adds a layer of counterparty risk to the revenue mix and shifts the timing of cash realization.

Implications for Enanta and sector peers

Enanta’s quarter highlights a broader industry dynamic: a royalty-based revenue stream from a large partner can deliver near-term stability while the company builds intrinsic value through its own pipeline. The MAVYRET royalties are a bridge, not a full engine, and investors will be watching whether the pipeline milestones—EPS-3903 IND, MRGPRX2 nomination, and Zelicapavir-related activities—can convert into meaningful top-line growth or license deals to diversify away from AbbVie’s sales cadence.

For sector peers, the Enanta print reinforces the appeal of royalty-backed models as a way to de-risk early-stage portfolios while maintaining optionality on late-stage opportunities. The absence of an EPS figure or a formal revenue forecast in this quarter means investors must lean on pipeline milestones and balance-sheet resilience to gauge upside. An earnings surprise could emerge if a late-stage partner or IND moves accelerate; otherwise, the emphasis remains on milestone-driven valuation rather than immediate earnings per share optics.

Bottom line

Enanta’s Q2 narrative is a quiet-but-steady one: a durable royalty stream backed by AbbVie sales, a strong liquidity position, and a slate of pipeline milestones that could re-rate the stock if milestones translate into tangible products. The absence of a disclosed EPS figure and revenue forecast keeps the focus on what matters next: IND timing, candidate nominations, and topline progression from the company’s own programs. In the meantime, the MAVYRET royalties keep the lights on, and the pipeline keeps the calendar turning toward 2026 and beyond.